Clinical trial
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary…
NCT00082212 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00082212 |
|---|---|
| Title | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Official title | A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Biological |
| Interventions | Cetuximab |
| Enrollment | 25 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | May 5, 2004 |
| Last update posted | Apr 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: